BIOR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BIOR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.
Biora Therapeutics's Capital Expenditure for the three months ended in Dec. 2023 was $-0.07 Mil. Its Cash Flow from Operations for the three months ended in Dec. 2023 was $-13.75 Mil.
GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.
The historical data trend for Biora Therapeutics's Capex-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biora Therapeutics Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Capex-to-Operating-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
Biora Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Capex-to-Operating-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Biora Therapeutics's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Biora Therapeutics's Capex-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Biora Therapeutics's Capex-to-Operating-Cash-Flow falls into.
Biora Therapeutics's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as
Capex-to-Operating-Cash-Flow | = | - Capital Expenditure | / | Cash Flow from Operations |
= | - (-0.103) | / | -48.499 | |
= | N/A |
Biora Therapeutics's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2023 is calculated as
Capex-to-Operating-Cash-Flow | = | - Capital Expenditure | / | Cash Flow from Operations |
= | - (-0.066) | / | -13.745 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biora Therapeutics (NAS:BIOR) Capex-to-Operating-Cash-Flow Explanation
Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.
Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.
Thank you for viewing the detailed overview of Biora Therapeutics's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Athyrium Opportunities Iii Co-invest 1 Lp | 10 percent owner | 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017 |
Surbhi Sarna | director | ONE PENUMBRA PLACE, ALAMEDA CA 94502 |
Aditya P. Mohanty | director, officer: Chief Executive Officer | 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501 |
Jill Ann Howe | director | C/O DTX PHARMA, INC., 10655 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO CA 92121 |
Athyrium Capital Management, Lp | 10 percent owner | 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017 |
Athyrium Opportunities Fund (a) Lp | 10 percent owner | 605 THIRD AVENUE, 22ND FLOOR, NEW YORK NY 10158 |
Hutan Hashemi | officer: Chief Compliance Officer | 4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122 |
Damon Silvestry | officer: Chief Operating Officer | 4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122 |
Jeffrey D. Alter | director | 4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122 |
Athyrium Opportunities Iii Acquisition Lp | 10 percent owner | 505 FIFTH AVENUE, 18TH FLOOR, NEW YORK NY 10017 |
Harry Stylli | director, officer: Chairman & CEO | 3595 JOHN HOPKINS CT, SAN DIEGO CA 92121 |
Matthew T Cooper | officer: Chief Scientific Officer | 4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122 |
Athyrium Opportunities Advisers Llc | 10 percent owner | 1209 AVENUE OF THE AMERICAS, NEW YORK NY 10104 |
Athyrium Opportunities Associates Gp Llc | 10 percent owner | 1209 AVENUE OF THE AMERICAS, NEW YORK NY 10104 |
Athyrium Opportunities Associates Lp | 10 percent owner | 1209 AVENUE OF THE AMERICAS, NEW YORK NY 10104 |
From GuruFocus
By Stock market mentor Stock market mentor • 01-09-2023
By Marketwired • 09-25-2023
By Marketwired • 09-05-2023
By sperokesalga sperokesalga • 02-16-2023
By Marketwired • 06-28-2023
By Marketwired • 11-06-2023
By sperokesalga sperokesalga • 05-08-2023
By Marketwired • 10-23-2023
By sperokesalga sperokesalga • 06-13-2023
By sperokesalga sperokesalga • 03-23-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.